Piramal Enterprises Consumer Products Division today announced the launch of Caladryl Diaper Cream. Unlike conventional diaper creams, Caladryl diaper cream acts 2 times faster toprotectand soothe baby’ skin from diaper rash.
Caladryl is the market leader in the anti-allergy and anti-itch topical application segment. It is India’s most prescribed lotion for anti-skin allergy and anti-skin irritation segment.
Commenting on the launch of Caladryl diaper cream, Mr. Kedar Rajadnye, Chief Operating Officer, Consumer Products Division, Piramal Enterprises Ltd. said“With the society welcoming the convenience and hygiene provided by diapers, they have become an integral part of any mother’s life. With extended use of wet diapers, diaper rash is also becoming a harsh reality. This diaper rash causes pain and discomfort, resulting in the baby crying continuously. This disrupts the mother’s routine and is a cause of great concern.Mothers are unaware of any self-care solutions to this critical problem.
Caladryl, which is an expert lotion for skin allergies with its equity of being used extensively amongst children and babies, has now launched Caladryl Diaper Cream for diaper rashes. It carries the same expertise and trustworthiness of the mother brand.”
Caladryl Diaper Cream is here to bust the myth that diaper rash creams need to get absorbed by the skin. Unlike a moisturising cream which gets absorbed, a diaper rash cream needs to form a protective layer on the skin to work effectively. Caladryl Diaper cream is specially formulated to be a thicker cream. It doesn’t get absorbed by the skin easily but forms a protective layer on the skin so that it can effectively block out the wetness from urine and the friction from the diaper and heal the rash quicker. It is proven to start working 2 times faster than ordinary diaper creams helping the baby heal faster so that he/she stops crying and more importantly the mother is relieved.
Caladryl Diaper Cream is dermatologically tested on sensitive skin. It contains zinc oxide, an ingredient which is approved by the US FDA as a skin protectant. It also contains olive oil and glycerine which are known to be mild and gentle on baby’s skin
About Consumer Products Business at Piramal Enterprises:
The Consumer Product Business is one of the fastest growing players in the Domestic Consumer Healthcare Market and is currently ranked 5th amongst all OTC players in India. The Business has a portfolio of brands like Saridon, Lacto Calamine, I range of Products (i-pill, i-know, i-can), Quik Kool, Polycrol, Jungle Magic, Tetmosol, Caladryl, Littles, Naturolax, LactoBacil plus etc. and has six brands amongst the top 100 Indian OTC brands. Most of the brands in the portfolio are either No 1 or No 2 in their respective categories. The business has a strong distribution footprint and covers all the 20k+ population towns across the country.
About Piramal Enterprises Limited
Piramal Enterprises Limited (PEL) is one of India’s large diversified companies, with a presence in Financial Services, Pharmaceuticals and Healthcare Insights & Analytics. PEL’s consolidated revenues were over US$1.3 billion in FY2017, with 51% of revenues generated from outside India.
In Financial Services, PEL provides comprehensive financing solutions to real estate companies. The division’s Corporate Finance Group (CFG) also provides senior and mezzanine growth capital to various businesses across varied sectors that are integral part of India’s growth story. The Division has also launched Distressed Asset Investing platform that will invest in equity and/or debt in assets across sectors (other than real estate) to drive restructuring with active participation in turnaround. The total funds under management under all these businesses are over US$5.5 billion. The Company has recently launched a retail housing finance vertical. The Company also has strategic alliances with top global funds such as APG Asset Management, Bain Capital Credit, CPPIB Credit Investment Inc. and Ivanhoé Cambridge (CDPQ). PEL also has long term equity investments worth ~US$1 billion in Shriram Group, a leading financial conglomerate in India.
In Pharma, through an end-to-end manufacturing capabilities across 13 global facilities and a large global distribution network to over 100 countries, PEL sells a portfolio of niche differentiated pharma products and provides an entire pool of pharma services (including in the areas of injectable, HPAPI etc.). The Company is also strengthening its presence in the Consumer Product segment in India.
PEL’s Healthcare Insights & Analytics business, Decision Resources Group, is the premier provider of healthcare analytics, data & insight products and services to the world’s leading pharma, biotech and medical technology companies and enables them to take informed business decisions.
PEL is listed on the BSE Limited and the National Stock Exchange of India Limited in India.